Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInvestment IncomeNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Fresenius Medical Care AG (FMS) Research & Development: 2009-2024

Historic Research & Development for Fresenius Medical Care AG (FMS) over the last 16 years, with Dec 2024 value amounting to $196.1 million.

  • Fresenius Medical Care AG's Research & Development rose 0.34% to $44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.8 million, marking a year-over-year decrease of 14.25%. This contributed to the annual value of $196.1 million for FY2024, which is 21.86% down from last year.
  • Fresenius Medical Care AG's Research & Development amounted to $196.1 million in FY2024, which was down 21.86% from $250.9 million recorded in FY2023.
  • Fresenius Medical Care AG's 5-year Research & Development high stood at $261.3 million for FY2021, and its period low was $196.1 million during FY2024.
  • Moreover, its 3-year median value for Research & Development was $241.0 million (2022), whereas its average is $229.3 million.
  • Its Research & Development has fluctuated over the past 5 years, first increased by 18.09% in 2021, then decreased by 21.86% in 2024.
  • Over the past 5 years, Fresenius Medical Care AG's Research & Development (MRY) stood at $221.2 million in 2020, then grew by 18.09% to $261.3 million in 2021, then decreased by 7.77% to $241.0 million in 2022, then rose by 4.14% to $250.9 million in 2023, then fell by 21.86% to $196.1 million in 2024.
  • Its Research & Development was $196.1 million in FY2024, compared to $250.9 million in FY2023 and $241.0 million in FY2022.